A META-ANALYSIS

[1]  D. Horsfall,et al.  The relative prognostic significance of total cathepsin D and HER‐2/neu oncogene amplification in breast cancer , 2007, International journal of cancer.

[2]  V. Kosma,et al.  Prognostic value of cathepsin-D expression in female breast cancer. , 1995, Anticancer research.

[3]  J. Isola,et al.  Stromal cell cathepsin D expression and long-term survival in breast cancer. , 1995, British Journal of Cancer.

[4]  S G Thompson,et al.  Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.

[5]  P. Boracchi,et al.  Prognostic indicators for early-stage breast-carcinoma .2. Value of cathepsin-d expression, detected by immunocytochemistry - a multiparametric study. , 1994, International journal of oncology.

[6]  T. Maudelonde,et al.  Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. , 1994, Human pathology.

[7]  A. Messori,et al.  Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. , 1994, The American journal of gastroenterology.

[8]  A. Berg,et al.  Relapse following discontinuation of antiepileptic drugs , 1994, Neurology.

[9]  C. Benz,et al.  Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Fuqua,et al.  Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Gerald,et al.  Immunohistochemical Detection of Cathepsin D in T2N0M0 Breast Carcinoma , 1994, The American journal of surgical pathology.

[12]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[13]  A Messori,et al.  Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. , 1993, Computer methods and programs in biomedicine.

[14]  K. Chang,et al.  Prognostic significance of immunohistochemical analysis of cathepsin D in low‐stage breast cancer , 1993, Cancer.

[15]  S. Leinster,et al.  Prognostic significance of cathepsin-D in patients with breast cancer. , 1993, British Journal of Cancer.

[16]  P. Rouanet,et al.  A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol , 1993, Cancer.

[17]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[18]  G. Striker,et al.  Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. , 1992, The American journal of pathology.

[19]  Z. Shao,et al.  Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. , 1992, Cancer research.

[20]  W. Gregory,et al.  Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Robert,et al.  The role of chemotherapy for node‐negative breast cancer , 1991, Cancer.

[22]  P. Pujol,et al.  Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. , 1990, Oncogene.

[23]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[24]  J. Cairns,et al.  Prognostic significance of the estrogen‐regulated protein, cathepsin D, in breast cancer. An immunohistochemical study , 1990, Cancer.

[25]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[26]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[27]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[28]  J. Simes,et al.  Total parenteral nutrition and cancer clinical trials , 1986, Cancer.

[29]  H. Rochefort,et al.  Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. , 1986, Endocrinology.

[30]  R. Peto,et al.  Overview of randomised trials of diuretics in pregnancy. , 1985, British medical journal.

[31]  A. Smith.  Clinical trials , 1984, The Medical journal of Australia.

[32]  H. Rochefort,et al.  Estradiol induced proteins in the MCF7 human breast cancer cell line. , 1979, Biochemical and biophysical research communications.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  G. Capitanio,et al.  Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. , 1995, European journal of cancer.

[35]  J. Foekens,et al.  Quality control of cathepsin-D measurement by the EORTC Receptor Study Group. , 1992, European journal of cancer.

[36]  L. Liotta,et al.  Cancer invasion and metastasis: positive and negative regulatory elements. , 1991, Cancer investigation.

[37]  Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[38]  R. Simes,et al.  Confronting publication bias: a cohort design for meta-analysis. , 1987, Statistics in medicine.